Primary refractory mm
WebFeb 4, 2024 · In phase I trials of patients with relapsed/refractory MM ... S., Singh, A. P. & Schinke, C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary ... WebFeb 2, 2024 · Refractory Myeloma Dr. Damian Green, MD of the Fred Hutchinson Cancer Center, generally defines Refractory Myeloma as: "disease that is progressing despite …
Primary refractory mm
Did you know?
WebJul 27, 2015 · In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular ... WebIntroduction. Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of …
WebEligible patients with primary double-refractory MM benefit the most from auto-HSCT, primarily when performed immediately after frontline therapy. While auto-HSCT is an … WebJul 5, 2024 · Progression-free survival estimates in 85 treated patients with primary double-refractory multiple myeloma for the entire cohort (a) and stratified by inclusion of ASCT …
WebJan 30, 2024 · Briefly, patients with relapsed MM, or RRMM to the last line of therapy, who received 1 to 3 previous anti-myeloma therapies, and were primary refractory or relapsed and refractory to lenalidomide ... WebB cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit. We report the case of a 61-year-old woman with primary refractory MM who presented with high expression of membrane BCMA and low …
WebApr 12, 2024 · A multicenter, prospective, single group, phase 2 study will be conducted on 81 patients presenting with refractory VF. After failure of 3 EES, each patient will receive direct intravenous injection of 20 mmol KCl instead of amiodarone. The primary outcome will be survival rate at hospital admission.
WebThe 1-year estimated progression-free survival from the time of transplant for the refractory group was 70% compared to 83% for the chemosensitive group (P=0.65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT. matt raney bioWebPrimary Refractory Disease Clinical trials have not yet been designed specifically for patients with primary refractory MM. “We treat [these] patients with what we already have, but we don't have clinical data supporting specific approaches in this type of patient, besides getting them to transplantation early and using a triplet or even a quadruplet as data … matt ramsey online auctionsWebJan 20, 2024 · Nine of the 15 enrolled patients had active, refractory disease with bone marrow blasts ranging from 7 to 83.9% prior to transplant. Complete remission was … matt rankin first national bankWebJun 6, 2024 · The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib … her heart hurtWebSep 28, 2024 · The current algorithms for the treatment of symptomatic newly diagnosed MM based on these two factors is shown in Fig. 1. In general, eligibility for ASCT is affected by age, performance status ... her heart for a compass bookWebNov 29, 2024 · Introduction: Despite the recent introduction of novel agents for multiple myeloma (MM), the disease remains incurable and invariably progresses through these … her heart is a cold iron meaningWebMay 14, 2015 · Patients who never achieve at least a MR to initial induction therapy and progress while on therapy are defined as “primary refractory.” Relapsed myeloma is … matt raney without hat